CD274 and non-small cell lung carcinoma: For example, in samples from patients enrolled in a phase II multicenter clinical trial (NCT03838848) [patients with advanced NSCLC treated with anti-PD-L1/CTLA-4 bispecific antibody (KN046)], researchers analyzed the impact of intratumoral heterogeneity using spatial proteomic and transcriptomic DSP and found spatially defined tumor and stromal signatures scores that could predict clinical response [74].